Predominance of large VLDL particles in metabolic syndrome, detected by size exclusion liquid chromatography

Clinical Biochemistry

Volumn 45, Issue 4-5, 2012, Pages 293-297

  Lucero, Diego ^a   Zago, Valeria ^a   López, Gustavo H ^b   Cacciagiú, Leonardo ^a   López, Graciela I ^a   Wikinski, Regina ^a   Nakajima, Katsuyuki ^a,c   Schreier, Laura ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b National Southern University   (Argentina)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

Adiponectin; Free fatty acids; Metabolic syndrome; Size exclusion HPLC; Triglyceride rich lipoproteins; VLDL

Indexed keywords

ADIPONECTIN; FATTY ACID; LIPID; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; ULTRAVIOLET RADIATION; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; ARGENTINA; ATHEROSCLEROSIS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; LIPOPROTEINS, VLDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PARTICLE SIZE; RISK; TRIGLYCERIDES; ULTRACENTRIFUGATION;

EID: 84857648040     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.12.013     Document Type: Article

References (26)

1. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
2. Okazaki M., Usui S., Hosaki S. Analysis of plasma lipoproteins by gel permeation chromatography. Handbook of lipoprotein testing 2000, 647-669. AACC Press, Washington DC. N. Rifai, G.R. Warnick, M.H. Dominiczak (Eds.).
3. Nakajima K., Nakano T., Tokita Y., Nagamine T., Inazu A., Kobayashi J., et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta 2011, 412:1306-1318.
4. Satoh A., Adachi H., Tsuruta M., Hirai Y., Hiratsuka A., Enomoto M., et al. High plasma level of remnant-like particle cholesterol in the metabolic syndrome. Diabetes Care 2005, 28:2514-2518.
5. Proctor S.D., Vine D.F., Mamo J.C. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002, 13:461-470.
6. Nakamura T., Obata J.E., Hirano M., Kitta Y., Fujioka D., Saito Y., et al. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis 2011, 218:163-167.
7. Gómez Rosso L., Meroño T., Benítez M.B., López G., Giunta G., D'Ambrosio M.L., et al. Low adiponectin levels in primary hypertriglyceridemic male patients. Nutr Metab Cardiovasc Dis 2009, 19:135-139.
8. 2. Clin Chem 1983, 29:2026-2030.
9. Assmann G., Jabs H., Kohnert U., Nolte W., Schriewer H. LDL (low density lipoprotein) cholesterol determination in blood serum following precipitation of LDL with polyvinyl sulphate. Clin Chim Acta 1984, 140:77-83.
10. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis assessment model: insulin and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
11. Schumaker V.N., Puppione D.L. Sequential flotation ultracentrifugation. Methods Enzymol 1986, 128:155-170.
12. Sasse J., Gallagher S.R. Staining proteins in gels. Curr Protoc Mol Biol 2003, Chapter 10:Unit 10.6.
13. Lucero D., Zago V., López G.I., Graffigna M., López G.H., Fainboim H., et al. Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome?. Clin Chim Acta 2011, 412:587-592.
14. Hara I., Okazaki M. High-performance liquid chromatography of serum lipoproteins. Methods Enzymol 1986, 129:57-78.
15. Okazaki M., Usui S., Ishigami M., Sakai N., Nakamura T., Matsuzawa Y., et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 2005, 25:578-584.
16. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gel. Clin Chim Acta 1993, 223:53-71.
17. Kinoshita M., Ohnishi H., Maeda T., Yoshimura N., Takeoka Y., Yasuda D., et al. Increased serum apolipoprotein B48 concentration in patients with metabolic syndrome. J Atheroscler Thromb 2009, 16:517-522.
18. Adiels M., Olofsson S.O., Taskinen M.R., Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
19. Packard C.J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003, 31:1066-1069.
20. Schreier L., Berg G., Zago V., Gonzalez A.I., Wikinski R. Kinetics of in vitro lipolysis of human very low-density lipoprotein by lipoprotein lipase. Nutr Metab Cardiovasc Dis 2002, 12:13-18.
21. Lewis G.F. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 1997, 8:146-153.
22. Adiels M., Borén J., Caslake M.J., Stewart P., Soro A., Westerbacka J., et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005, 25:1697-1703.
23. Burns S.F., Arslanian S.A. Waist circumference, atherogenic lipoproteins, and vascular smooth muscle biomarkers in children. J Clin Endocrinol Metab 2009, 94:4914-4922.
24. Weiss R., Otvos J.D., Flyvbjerg A., Miserez A.R., Frystyk J., Sinnreich R., et al. Adiponectin and lipoprotein particle size. Diabetes Care 2009, 32(7):1317-1319.
25. Vergès B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis 2010, 211:353-360.
26. Ng T.W., Watts G.F., Farvid M.S., Chan D.C., Barrett P.H. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?. Diabetes 2005, 54:795-802.